Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE

Nicholas James, Lazaros Andronis, Ilias Goranitis, Ann Pope, Sarah Pirrie, Darren Barton, Adam Daunton, Duncan McLaren, Lucinda Billingham

Research output: Contribution to conference (unpublished) › Poster

1 Article

1 results

2016
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer: Clinical Trial Report
James, N., Pirrie, S., Pope, A., Barton, D., Andronis, L., Goranitis, I., Collins, S., McLaren, D., O'Sullivan, J., Parker, C., Porfiri, E., Staffurth, J., Stanley, A., Wylie, J., Beesley, S., Birtle, A., Brown, J., Chakraborti, P., Russell, M. & Billingham, L., 31 Jul 2016, In: Health Technology Assessment. 20, 53, 20530.
Research output: Contribution to journal › Article › peer-review

Open Access
18 Citations (Scopus)